{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-219377","form_type":"8-K","ticker":"KYTX","cik":"0001994702","company_name":"Kyverna Therapeutics, Inc.","filed_at":"2026-05-12T20:05:31+00:00","discovered_at":"2026-05-12T20:07:00.310971+00:00","generated_at":"2026-05-12T21:33:21.410489+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Kyverna reports Q1 net loss $39.7M; initiates rolling BLA for miv-cel in SPS","bullets":["Cash, cash equivalents and marketable securities of $236.4M as of March 31, 2026; cash runway expected into 2028.","Net loss of $39.7M ($0.66 per share) for Q1 2026; R&D expenses $30.1M, G&A $11.3M.","Initiated rolling BLA submission for miv-cel in stiff person syndrome after positive pre-BLA meeting with FDA; completion expected Q4 2026.","Primary analysis of KYSA-8 trial in SPS showed statistically significant durable benefit across all endpoints; 100% of patients free of immunotherapies at week 16.","Appointed Nadia Dac as Chief Commercial Officer; enrollment ongoing in Phase 3 gMG trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-219377","json":"https://secwatch.observer/filing/0001193125-26-219377.json","markdown":"https://secwatch.observer/filing/0001193125-26-219377.md","text":"https://secwatch.observer/filing/0001193125-26-219377.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1994702/000119312526219377/0001193125-26-219377-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1994702/000119312526219377/kytx-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T21:33:21.410489+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"15f9eec7f770e0f4ca6a7d8f8c19d2a666814a90","claim":"Kyverna Therapeutics, Inc. reported financial results for first quarter ended March 31, 2026.","evidence_excerpt":"On May 12, 2026, Kyverna Therapeutics, Inc. (the “Company”) issued a press release providing a business update and reporting financial results for the quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1994702/000119312526219377/0001193125-26-219377-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}